# US 2025/0082647 A1 · Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082647 A1
- Document ID: US20250082647A1
- Status: Published application
- Kind: A1
- Application number: 18/726,500
- Filed: 2023-01-03
- Published: 2025-03-13
- Earliest claimed: 2022-01-04
- Assignees: Immungenetics AG
- Applicants: Immungenetics AG
- Inventors: Markus KROHN
- Web page: https://patentgrep.com/patent/US20250082647A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates in a first aspect to a compound of formula (I) for use in the treatment and/or in prevention of Alzheimer's dementia, wherein the compound of formula (I) is administered in a dosage<20 mg. In a second aspect, the invention relates to a pharmaceutical composition comprising the compound according to the first aspect.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for treating and/or preventing Alzheimer's dementia in a subject, wherein the method comprises:
administering a compound of formula (I);
wherein:
R1 is selected from the group consisting of hydrogen atom, halogen atom, methoxy group, perhalogenated alkyl group and —X-C1 to C2 alkyl group, wherein X is either a sulphur atom or an oxygen atom;
R2 is a hydrogen atom or a methyl group;
R3, R4 are independently of each other either a hydrogen atom or C1 to C4 alkyl group or form together a six membered alkyl ring which comprises at least one further nitrogen atom, wherein the at least one further nitrogen is substituted with a C1 to C3 alkyl-R5 group, wherein R5 is a hydrogen atom or a hydroxyl group;
n is zero or 1;
m is zero or an integer selected from the range of from 1 to 4;
p is zero or an integer selected from the range of from 1 to 3;
wherein the compound of formula (I) is administered in a dosage≤20 mg per day of administration.

### Claim 12 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered in a dosage in the range of from 2 to 20 mg per day of administration.

### Claim 13 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is a compound that has formula (Ia):
wherein
R1 is selected from the group consisting of methoxy group, trifluoromethyl group and thioethyl group;
R2 is a hydrogen atom or a methyl group;
R3, R4 are both a methyl group or form together a six membered alkyl ring, which comprises one further nitrogen atom, wherein the one further nitrogen is substituted with a methyl group,
n is zero or 1.

### Claim 14 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered in a dosage in the range of from 5 to 15 mg per day of administration.

### Claim 15 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is a pharmaceutically acceptable salt of formula (I), wherein the pharmaceutically acceptable salt comprises one or more anion(s) selected from the group consisting of chloride, sulfate, mesylate, besylate, tosylate, fumarate, malonate, malate, maleate, succinate, lactate, glycolate, citrate, aspartate and mandelate.

### Claim 16 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is selected from the group consisting of levomepromazine, trifluoperazine, thiethylperazine, and pharmaceutically acceptable salts of these compounds.

### Claim 17 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is thiethylperazine maleate, and wherein the thiethylperazine maleate is administered in a dosage≤31.62 mg.

### Claim 18 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered orally or rectally.

### Claim 19 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered as a pharmaceutical composition comprising the compound of formula (I) and a pharmaceutically acceptable excipient, wherein the preparation contains in the range of 2 to 20 mg of the compound of formula (I),.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutical composition is in the form of a solution suitable for injection.

### Claim 21 (depends on 15)

The method of claim 15, wherein formula (I) of the pharmaceutically acceptable salt of formula (I) is selected from the group consisting of levomepromazine, trifluoperazine, thiethylperazine.

### Claim 22 (depends on 15)

The method of claim 15, wherein the pharmaceutically acceptable salt of formula (I) is administered orally or rectally.

### Claim 23 (depends on 15)

The method of claim 15, wherein the pharmaceutically acceptable salt of formula (I) is administered as a pharmaceutical composition comprising the pharmaceutically acceptable salt of formula (I) and a pharmaceutically acceptable excipient, wherein the preparation contains in the range of 2 to 20 mg of the compound of formula (I).

### Claim 24 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered in a dosage in the range of 6 to 13.5 mg per day of administration.

### Claim 25 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered in a dosage in the range of 6 to 7 mg per day of administration.

### Claim 26 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is administered in a dosage in the range of 12.5 to 13.5 mg per day of administration.

### Claim 27 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is a pharmaceutically acceptable salt of formula (I), wherein the pharmaceutically acceptable salt comprises one or more anion(s) selected from malate and/or maleate.

### Claim 28 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is a pharmaceutically acceptable salt of formula (I), wherein the pharmaceutically acceptable salt comprises the anion maleate.

### Claim 29 (depends on 11)

The method of claim 11, wherein the compound of formula (I) is selected from the group consisting of levomepromazine, and thiethylperazine.

### Claim 30 (depends on 11)

The method of claim 11, wherein treating Alzheimer's dementia comprises increasing the subject's plasma Abeta1-40 concentration.
